Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced the launch of its artificial intelligence-powered good manufacturing practices (GMP) manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform combines the company's PDAOAI technology with advanced robotics provided through its collaboration with TechForce Robotics, aiming to support pharmaceutical, biotechnology, and advanced therapeutics companies in modernizing manufacturing operations through AI-driven workflows, digital quality systems, and intelligent automation.
According to the press release, the platform is designed to support electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions, and process monitoring. Oncotelic also plans to showcase progress with its Deciparticle nanomedicine platform, including SAPU003, its clinical-stage intravenous everolimus program currently being evaluated in a Phase 1b study. The announcement underscores the growing importance of AI and automation in pharmaceutical manufacturing, potentially reducing costs, improving quality control, and accelerating time-to-market for new therapies.
The launch represents a strategic move for Oncotelic, which has traditionally focused on oncology and immunotherapy product development. By offering GMP manufacturing services, the company positions itself as a partner to other drug developers, leveraging its proprietary AI platform to address industry challenges such as batch record consistency, regulatory compliance, and process optimization. The collaboration with TechForce Robotics brings specialized automation expertise, which could enhance the platform's capabilities in handling complex manufacturing tasks.
For more details, the full press release is available at https://ibn.fm/upnBW. Oncotelic's CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued U.S. patents, underscoring the company's innovative foundation. The company also owns 45% of GMP Bio, a joint venture advancing its own pipeline of drug candidates, and develops PDAOAI for drug discovery, lab automation, and AI-assisted GMP manufacturing.
The platform's implications are significant for the pharmaceutical industry, where AI adoption is accelerating. By digitizing GMP workflows and integrating intelligent automation, companies can potentially reduce human error, enhance traceability, and streamline audits. This could lead to faster regulatory approvals and lower production costs, ultimately benefiting patients through more efficient drug development and supply chains. Oncotelic's initiative aligns with broader industry trends toward Industry 4.0 in pharma, where data-driven manufacturing is becoming a competitive differentiator.
Investors and industry observers will be watching how Oncotelic's platform performs in real-world applications, particularly given the stringent regulatory environment for GMP manufacturing. The company's existing relationships, such as its connection to SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, may provide a foundation for practical implementation. The platform's success could also influence Oncotelic's valuation and partnerships, as the market for AI-driven pharma manufacturing services is expected to grow.
